CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis - Li, Shenglong; Liu, Fei; Zheng, Ke; Wang, Wei; Qiu, Enduo; Pei, Yi; Wang, Shuang; Zhang, Jiaming; Zhang, Xiaojing (Molecular cancer, 2021)
Keywords: Analysis; Animals; Antimitotic agents; Antineoplastic agents; Apoptosis; Bone Neoplasms - drug therapy; Bone Neoplasms - etiology; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Cancer therapies; Cell growth; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - metabolism; Chemotherapy; circDOCK1; Cisplatin; Cisplatin - pharmacology; Cisplatin resistance; Cloning; Cytoplasm; Development and progression; Disease Models, Animal; DNA microarrays; Drug Resistance, Neoplasm - genetics; Female; Gene expression; Gene Expression Regulation, Neoplastic; Genes; Health aspects; Humans; IGF1R; Immunoprecipitation; Metastasis; Mice; MicroRNA; MicroRNAs; MicroRNAs - genetics; miR-339-3p; Operating systems; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - etiology; Osteosarcoma - metabolism; Osteosarcoma - pathology; rac GTP-Binding Proteins - genetics; Reagents; Receptor, IGF Type 1 - genetics; Receptor, IGF Type 1 - metabolism; RNA Interference; RNA, Circular - genetics; Sarcoma; Signal Transduction; Therapeutic targets; Tumor cell lines; Tumorigenesis; Tumors; Xenograft Model Antitumor Assays; United States--US; China; Japan; Cisplatin resistance; OS; circDOCK1; miR-339-3p; IGF1R